Cilostazol
Brand names: Cilostazol
At a glance
- Medicare prescriptions, 2024
- 518,304
- Medicare drug cost
- $10.7M
- Average cost per prescription
- $20.57
- Clinicians who prescribed it
- 17,556
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: CONTRAINDICATED IN HEART FAILURE PATIENTS Cilostazol tablets are contraindicated in patients with heart failure of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Internal Medicine 17.0%
- Family Medicine 15.9%
- Nurse Practitioners 13.3%
- Vascular Surgery 12.8%
- Cardiology 10.9%
- General Practice 9.2%
- Interventional Cardiology 8.9%
- Physician Assistants 4.9%
- General Surgery 1.5%
- Geriatric Medicine 0.9%
- Cardiothoracic Surgery 0.7%
- Podiatrists 0.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 10% from 2019 to 2024.
Biggest change by state since 2019
- Arizona +4%
- Louisiana +4%
- Washington −0%
- Arkansas −3%
- North Carolina −3%
- New York (smallest change) −23%
- Massachusetts (smallest change) −22%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Apotex Corp.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white round tablet, 7 mm | APO CIL 50 |
| 100 mg | white round tablet, 9 mm | APO CIL 100 |
Aurobindo Pharma Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white round tablet, 6 mm | CI 50 |
| 100 mg | white round tablet, 8 mm | CI 100 |
Avkare
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white round tablet, 9 mm | APO CIL 100 |
Avpak
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white round tablet, 7 mm | APO CIL 50 |
| 100 mg | white round tablet, 9 mm | APO CIL 100 |
Slate Run Pharmaceuticals, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white round tablet, 9 mm | YH205 |
| 100 mg | white round tablet, 10 mm | YH210 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.